Mandate

Vinge advises Isofol in conjunction with capital procurement

Vinge has advised Isofol Medical AB (publ), First North Growth Market Premier, in connection with its rights issue in the total amount of MSEK 150 and, conditional upon oversubscription in respect of the rights issue, a directed new issue of shares of a total amount of MSEK 30.

Isofol has convened an extraordinary general meeting which is proposed to grant authority to the board of directors to adopt resolutions concerning the new issues of shares. The rights issue is fully   underwritten through underwriting undertakings and guarantee obligations.

Vinge’s team primarily consisted of Anders StridWibeke SorlingJenny Sandlund (all Capital Markets) as well as Victor Ericsson and Emelie Svanberg (Tax).

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025